



2017 ANNUAL REPORT



AtlantiCare
THE CANCER CARE INSTITUTE

A member of Geisinger

Fox Chase Cancer Center Partner

Table of Contents

Oncology Program Leadership and Staff.....	3
A Comprehensive Approach to Quality Care	4
Operations Leadership Corner.....	5
2016 - 2017 Highlights and Achievements.....	6
Oncology Data Services.....	8
Cancer Registry Data – 2016 Analytic Cases.....	9
Outcomes.....	12
Providing Exceptional Cancer Care Close to Home	16
Nurse Navigator’s Corner.....	17
Taking Care and Giving Back.....	18
AtlantiCare Cancer Committee Members.....	19

Published December 2017



AtlantiCare Cancer Care Institute

A Fox Chase Cancer Center Partner

ONCOLOGY PROGRAM LEADERSHIP AND STAFF



James Wurzer, M.D., Ph.D.

Medical Director, Oncology Program
Medical Director, Radiation Oncology
Adjunct Associate Member, Radiation
Oncology, Fox Chase Cancer Center



Lacey Peterman

Director, Oncology Operations



John D. Lorenzetti, M.D., FACS

Medical Director, Breast Health Program



Desiree Jangha, Ph.D., DABR

Director, Medical Physics,
Radiation Therapy Services



Maria Hendricks, M.S.N., R.N., CCRP

Assistant Vice President,
Oncology Services
Regional Administrator, Central Market



**Maria Victoria Roque, B.S.N.,
R.N., OCN**

Clinical Manager, Medical Oncology



Frank Carpenter

Corporate Director, Oncology Operations



**DeAnnette Stanton-Cross, B.A.,
OPN-CG**

Oncology Program Manager
Community Outreach Coordinator

A COMPREHENSIVE APPROACH TO QUALITY CARE

The AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, provides comprehensive screening, diagnosis, treatment and survivorship planning for the most common types of cancer we see in our community — including breast, lung, prostate, colorectal and women’s reproductive cancers. As a trusted partner in the fight against cancer, we continue to sharpen our focus on treating this disease with a multidisciplinary team approach.

Our approach brings together specialists from each patient care discipline to collaboratively develop site-specific treatment plans for every patient using current evidence-based medical guidelines. This approach also incorporates the respective expertise of our oncology nurse navigators, clinical nutritionists, social workers, palliative care, behavioral health and pain management specialists and other disciplines to address the various needs of patients with cancer. In 2016, we instituted a dedicated Financial Counselor to assist patients and families with access to financial resources. The Financial Counselor is a direct point of contact for patients’ questions related to out-of-pocket costs and navigation of available financial resources.


In 2016, we enhanced our oncology services with the addition of a new specialty program dedicated to the treatment of complex gastrointestinal (GI) malignancies. In addition to colon and rectal cancers, this program provides all-encompassing, expert care for tumors diagnosed in the gallbladder, pancreas, esophagus, liver, appendix and other areas of the GI tract.

In 2017, we also initiated an expansion of our oncology nurse navigator program to provide dedicated support to patients diagnosed with GI cancers, as well as those with lung cancer and prostate cancer. This site-specific navigator program allows us to better serve patients by providing one point of contact throughout the treatment process to make it easier for patients to follow through on the recommendations of their treatment team.


Another key area of growth for us last year was the enhancement of our survivorship program, which supports patients in the months and years after their treatment ends. Cancer survivors have special needs for follow-up (surveillance), testing and lifestyle considerations. Our survivorship program is designed to meet those needs through individualized health monitoring and wellness care. Through this program, patients receive a personalized plan of follow-up care.

The oncology team at AtlantiCare is proud to have earned national accreditation from the American College of Surgeons Commission on Cancer and the American College of Radiology. We believe in providing the quality, cutting-edge cancer care that our patients need and deserve.

Sincerely,



James C. Wurzer, M.D., Ph.D.
Medical Director, Oncology Program;
Medical Director, Radiation Oncology,
AtlantiCare Cancer Care Institute,
a Fox Chase Cancer Center Partner



Maria Hendricks, M.S.N., R.N., CCRP
Assistant Vice President, Oncology Services
AtlantiCare Cancer Care Institute,
a Fox Chase Cancer Center Partner

Adjunct Associate Member, Department
of Radiation Oncology, Fox Chase Cancer Center

OPERATIONS LEADERSHIP CORNER

Over the past year, the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, has seen significant advances. In 2016, we invested in new technologies, infrastructure and expertise to support the continued growth of our oncology programs and services.

To ensure our patients have access to the latest treatment technologies, we purchased two of the latest-generation linear accelerators for our Radiation Oncology department last year. AtlantiCare radiation oncologists use these devices to deliver precisely focused beams of X-ray energy to shrink or eliminate solid-tumor cancers in major organs and other areas within the body. In particular, external-beam radiation therapy is widely used for prostate, breast and lung cancer, three of the most common malignancies in our community.

In addition, as part of our whole-person approach to treating cancer, we hired a financial counselor to join our multidisciplinary team in 2016. This individual is dedicated to working closely with pharmaceutical companies to ensure our patients have access to the medicines and treatments they need, without regard for an individual's financial abilities.

It's important that our patients have even greater choices of qualified providers for their care. To meet this need, we also recently expanded our team with the addition of a new medical oncologist in the Department of Medical Oncology. In the coming year, we will be adding more specialists, medical oncology and hematology to this growing team.

The launch of a cancer survivorship program in partnership with Carevive Systems was another key accomplishment of the AtlantiCare Cancer Care Institute last year. This program is focused on the follow-up care and future needs of patients once they have completed treatment.

In every area of its clinical operations, AtlantiCare remains committed to bringing the best cancer treatments and doctors to southern New Jersey. We believe you should be close to home and your loved ones when you are being treated for cancer. With AtlantiCare as your partner, you don't have to drive to another state or outside the region to find the specialty cancer care you need.

Sincerely,



Frank Carpenter
Corporate Director, Oncology Operations



Lacey Peterman
Director, Oncology Operations



Maria Victoria Roque, B.S.N., R.N., OCN
Clinical Manager, Medical Oncology

2016 - 2017 HIGHLIGHTS AND ACHIEVEMENTS

- The Oncology Program achieved:
 - American College of Surgeons Commission on Cancer (ACOS) re-accreditation, including four commendations.
 - Association of Community Cancer Centers (ACCC) program membership.
 - CEO (Chief Executive Officer) Cancer Gold Standard workplace wellness accreditation.
- AtlantiCare continued its participation in the Centers for Medicare & Medicaid Services (CMS) Innovation Center's Oncology Care Model (OCM), which focuses on care coordination appropriateness and access for Medicare beneficiaries receiving chemotherapy.
- All eligible RNs have earned or maintained certification as an Oncology Certified Nurse (OCN®).
- AtlantiCare expanded its nurse navigation services to further enhance transition of care.
- Our oncology nursing team participated in the Healing Arts for Nurses week.
- Maria Hendricks presented an AtlantiCare case study at the Oncology Service Line Management and Optimization Q1 Productions Conference. Her presentation was titled "Case Study: Delivering Oncology Service Line Excellence in the Community Setting."



7TH ANNUAL RELAY FOR LIFE
DR. WURZER WAS PRESENTED WITH
THE HONORARY HEALTHCARE CHAMPION AWARD.

June 9, 2017 – Mainland High School, Linwood

Relay For Life is not just an event, but a life-changing experience. This year, Relay For Life of Linwood raised over \$50,000, with 500 participants and 50 survivors, all of which was made possible by the support of AtlantiCare.



SURVIVORS ARE OUR SUPERHEROES EVENT

AtlantiCare Cancer Care Institute Celebrates and Honors Survivors

June 13, 2017 – Egg Harbor Township | June 14, 2017 – Cape May Court House



ONCOLOGY DATA SERVICES

AtlantiCare Cancer Care Institute is accredited by the American College of Surgeons Commission on Cancer (CoC). The CoC is a consortium of professional organizations dedicated to improving the survival and quality of life for cancer patients by establishing evidenced-based national standards and by monitoring the quality of cancer care at accredited programs. The National Cancer Database (NCDB) is a nationwide cancer database of patients treated at CoC-accredited programs.

The Cancer Registry team at the AtlantiCare Cancer Care Institute is responsible for capturing a complete history, diagnosis, first course of treatment and health status for every cancer patient at AtlantiCare in a timely manner. Each patient is followed for the course of his or her lifetime after diagnosis. The Cancer Registry team also organizes and participates in multidisciplinary oncology conferences and supports the AtlantiCare Cancer Committee in addition to the cancer program.



AtlantiCare uses registry data for research and to evaluate patient outcomes and the allocation of resources within the cancer program. In addition, we use the data in our community health needs assessments and in our community education and outreach activities to address identified needs in the area. Registry data is submitted to the NCDB and to the New Jersey State Department of Health Cancer Registry for reporting of National Quality Measures.

The AtlantiCare Cancer Committee utilizes the NCDB's accountability reporting tool to monitor our quality performance and outcomes, and to serve as a benchmark to focus quality improvement opportunities that support high-quality care.

A handwritten signature in black ink that reads "Cheryl Eget".

Cheryl Eget, CTR
Supervisor, Oncology Data Services

CANCER REGISTRY DATA – 2016 ANALYTIC CASES*



PRIMARY SITE	TOTAL	MALE	FEMALE
ORAL CAVITY & PHARYNX	23	17	6
Tongue	11	7	4
Salivary Glands	2	1	1
Gum & Other Mouth	2	2	0
Nasopharynx	1	1	0
Tonsil	4	4	0
Hypopharynx	2	2	0
Other Oral Cavity & Pharynx	1	0	1
DIGESTIVE SYSTEM	140	65	75
Esophagus	5	5	0
Stomach	9	4	5
Small Intestine	8	5	3
Colon (excluding Rectum)	53	19	34
Cecum	15	5	10
Appendix	4	1	3
Ascending Colon	10	3	7
Hepatic Flexure	1	1	0
Transverse Colon	3	1	2
Splenic Flexure	1	0	1
Descending Colon	5	2	3
Sigmoid Colon	10	4	6
Large Intestine, NOS	4	2	2
Rectum & Rectosigmoid	25	12	13
Rectosigmoid Junction	5	2	3
Rectum	20	10	10
Anus, Anal Canal & Anorectum	4	1	3
Liver & Intrahepatic Bile Duct	12	9	3
Gallbladder	4	2	2
Other Biliary	6	3	3
Pancreas	11	4	7
Retroperitoneum	1	1	0
Other Digestive Organs	2	0	2
RESPIRATORY SYSTEM	123	74	49
Larynx	9	7	2
Lung & Bronchus	114	67	47
BONES & JOINTS	1	1	0
Bones & Joints	1	1	0
SOFT TISSUE	3	1	2
Soft Tissue (including Heart)	3	1	2
SKIN EXCLUDING BASAL & SQUAMOUS	9	3	6
Melanoma – Skin	7	2	5
Other Non-Epithelial Skin	2	1	1
BREAST	183	2	181
Breast	183	2	181

CANCER REGISTRY DATA – 2016 ANALYTIC CASES* (continued)

PRIMARY SITE	TOTAL	MALE	FEMALE
FEMALE GENITAL SYSTEM	58	0	58
Cervix Uteri	12	0	12
Corpus & Uterus, NOS	37	0	37
Corpus Uteri	35	0	35
Uterus, NOS	2	0	2
Ovary	7	0	7
Vulva	1	0	1
Other Female Genital Organs	1	0	1
MALE GENITAL SYSTEM	75	75	0
Prostate	73	73	0
Testis	2	2	0
URINARY SYSTEM	20	9	11
Urinary Bladder	9	4	5
Kidney & Renal Pelvis	11	5	6
EYE & ORBIT	1	0	1
Eye & Orbit	1	0	1
BRAIN & OTHER NERVOUS SYSTEM	23	11	12
Brain	11	6	5
Cranial Nerves, Other Nervous System	12	5	7
ENDOCRINE SYSTEM	14	4	10
Thyroid	12	3	9
Other Endocrine including Thymus	2	1	1
LYMPHOMA	42	21	21
Hodgkin's Lymphoma	4	2	2
Non-Hodgkin's Lymphoma	38	19	19
NHL - Nodal	29	16	13
NHL - Extranodal	9	3	6
MYELOMA	4	2	2
Myeloma	4	2	2
LEUKEMIA	11	8	3
Lymphocytic Leukemia	7	6	1
Myeloid & Monocytic Leukemia	4	2	2
Acute Myeloid Leukemia	3	1	2
Chronic Myeloid Leukemia	1	1	0
MESOTHELIOMA	1	1	0
Mesothelioma	1	1	0
MISCELLANEOUS	22	9	13
Miscellaneous	22	9	13
TOTAL	753	303	450

*Cases for which AtlantiCare provided the initial diagnosis of cancer and/or for which AtlantiCare contributed to the patient's first course of treatment.

CANCER REGISTRY DATA – 2016 ANALYTIC CASES* (continued)




OUTCOMES

QUALITY PERFORMANCE MEASURES

Below are the American College of Surgeons Commission on Cancer (CoC) quality performance benchmark standards comparing AtlantiCare with other CoC organizations in New Jersey and the United States.

CoC standard for breast-conserving surgery and radiation therapy in breast cancer



Radiation is administered within 1 year (365 days) of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer.

CoC standard for image or palpation-guided needle biopsy (core or FNA) in breast cancer





Image or palpation-guided needle biopsy (core or FNA) is performed to establish diagnosis of breast cancer.


OUTCOMES *(continued)*

CoC standard for regional lymph nodes in surgically resected colon cancer



At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

CoC standard for systemic chemotherapy in surgically resectable lung cancer



Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node-positive (pN1) and (pN2) NSCLC.

OUTCOMES *(continued)*

QUALITY IMPROVEMENT: CERVIX CARCINOMA REVIEW

Reporting year: 2017

Accession year reviewed: 2015/2016

Number of cases reviewed: 8

Guideline: NCCN Guidelines® for Cervical Cancer Version 1.2018

Reviewer: Vasthi Christensen Wilson, M.D., MSc

Date presented: December 7, 2017



Vasthi Christensen Wilson, M.D., MSc

Vital to the success of the AtlantiCare Cancer Care Institute is continuous evaluation of performance in order to improve patient outcomes, emphasizing a professional commitment to safety and quality. This year, the Cancer Committee designated cervical carcinoma for an in-depth analysis to assess and verify if cancer program patients are evaluated and treated according to evidence-based national treatment guidelines. Cancer of the uterine cervix is the third most common cancer diagnosis and cause of death among gynecologic cancers in the United States. This formal review with analysis results represents a full evaluation of patients diagnosed with cervical cancer between July 2015 and November 2016. Results are presented to the Cancer Committee and documented in Cancer Committee minutes.

Initial evaluation of patients presenting to the AtlantiCare Cancer Care Institute with the diagnosis of cervix carcinoma was considered appropriate when the following criteria were documented/met: history/physical examination (including documentation of pelvic examination results), cervical biopsy, standard imaging and standard blood work. Patients were staged appropriately utilizing American Joint Committee on Cancer (AJCC) and/or Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging methods. Review of the workup of these patients was concordant with evidence-based national guidelines in all cases.

Treatment for this patient cohort included standard systemic chemotherapy consisting of either single-agent cisplatin or carboplatin delivered weekly during the course of the radiation. Pelvic external beam radiation therapy (EBRT) was prescribed to a dose of 45Gy, followed by intracavitary high-dose-rate (HDR) brachytherapy for an additional 25 to 30Gy. Treatment plan criteria were considered met if the recommended chemoradiotherapy was documented as administered, or as recommended but not administered for reasons stated in the medical record (i.e., contraindication, comorbidities, patient refusal or noncompliance). Review of treatment plans for these patients was concordant with evidence-based national guidelines in all cases.

In summary, this analysis confirms compliance with national guidelines. Documentation of collaborative coordination of care between medical oncology, gynecology and radiation oncology was evident. High-quality clinical services, including state-of-the-art pretreatment evaluation, staging, individualized treatment and clinical follow up, were verified as provided for AtlantiCare cervical cancer patients.

OUTCOMES *(continued)*

DEPARTMENT OF MEDICAL ONCOLOGY AND INFUSION SERVICES STUDY Improving Documentation of Adverse Reactions

INTRODUCTION

Reports of hypersensitivity/allergic reactions are quite rare and occur 5% of the time across all drugs.¹ Signs and symptoms of hypersensitivity/allergic reactions include throat or tongue swelling, wheezing, increased respiratory rate, decreased blood pressure, rash and itchiness. These signs and symptoms could be representative of a life-threatening reaction that requires the prompt attention of a healthcare team. Preventive strategies should be implemented to assess, treat and manage these patients. Appropriate documentation and follow-up of the event is also essential. The purpose of this performance improvement project was to validate if an improvement in adverse reaction documentation occurred at our cancer centers following implementation of the revised electronic documentation tool.

METHODS

This retrospective evaluation included patients at the cancer center who were reported to have a hypersensitivity reaction during chemotherapy, biotherapy or premedication administration from March 2015 to June 2017. A documentation tool was revised for adverse reactions and implemented in November 2016 with the help of informatics, pharmacy and nursing. The oncology clinical manager worked with the pharmacists to assess the adverse reaction documentation tool for optimization. Nurses and providers were educated by the oncology clinical nursing manager on the appropriate documentation process to include adverse reactions in the electronic health record. Progress notes in the electronic health record were reviewed for compliance.

RESULTS

A total of 48 patients were included in this evaluation. Prior to implementation of the electronic documentation tool from March 2015 to October 2016, there were 36 patients with a reported hypersensitivity reaction. The hypersensitivity protocol was followed for all 36 patients (100%). Only 3 patients (8.3%) had the adverse reaction documentation completed. Nursing documentation was completed for 31 patients (86.1%), and physician documentation was completed for 12 patients (33.3%). Nursing and provider education was completed by the oncology nursing manager. From November 2016 to June 2017 adverse reaction and progress notes in the electronic health record were reviewed. Only 12 patients with hypersensitivity reactions were documented. Eleven out of 12 patients (91.6%) had adverse reaction documentation completed. Nursing documentation was completed for 6 patients (50%), and physician documentation was completed for 6 patients (50%).

CONCLUSION

Following the implementation of the revised adverse reactions tool, compliance for the respective documentation improved from 8.3% to 91.6%. Changes to the adverse reaction documentation made it easier to use, and education helped reinforce appropriate documentation. Deficiencies were noted in progress note documentation. The team plans to continue to strive for 100% compliance and will continue to monitor. Future improvements strive to streamline and standardize the progress note process through the use of smart templates built within the electronic health record.



Hien T. Nguyen, Pharm.D., BCPS

Contributing Authors:

*Tamara Karcheski, BSPharm, RPh
George T. Hewlett, BSPharm, RPh*

¹Syrigou E, Makrilia N, Koti I, et al. *Hyper-sensitivity reactions to antineoplastic agents: an overview.* Anticancer Drugs. 2009; 20:1-6.

PROVIDING EXCEPTIONAL CANCER CARE CLOSE TO HOME

When the diagnosis is cancer, patients don't have to drive far to find expert quality care or to get a second opinion. From evaluation and diagnosis to treatment, psychosocial support, wellness services and recovery — everything patients and their families need is close by at the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner.

AtlantiCare Cancer Care Institute is accredited by both the American College of Surgeons Commission on Cancer for our overall program and by the American College of Radiology for radiation therapy.

CLINICAL SERVICES

- Medical oncology and infusion services
- Radiation oncology
- Surgical oncology
- Clinical trials
- Diagnostic imaging

SUPPORT SERVICES

- Oncology social worker
- Oncology nurse navigators
- Mammography scheduling
- Nutrition counseling with a registered dietitian
- Gilda's Club at AtlantiCare: integrated psychosocial support programs on-site, including support groups, education and healthy lifestyle workshops that promote health and well-being
- Transportation to medical appointments
- Behavioral health services
- Palliative care program
- Pastoral care program
- Respecting Choices program for Advance Care Planning
- Financial counseling
- Community education and cancer screening

ADVANCING CANCER CARE THROUGH CLINICAL RESEARCH

Clinical trials (research studies) help medical researchers understand more about cancer and its treatment. Everything we know today about how to treat cancer was learned through a clinical trial. The AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, is proud to offer patients with cancer in our community the chance to take part in clinical trials that test new ways to diagnose and/or treat cancer and new ways to improve the lives of those with cancer.

Joining a clinical trial is a personal decision. People take part in clinical trials for many reasons, including gaining access to new treatments that are not yet widely available and wanting to make a difference for others who will be diagnosed with cancer in the future. Patients may choose to take part or not, and they are free to leave at any time.

The AtlantiCare Oncology Clinical Research Coordinator helps patients understand what clinical trials may be available for you and for your type of cancer. The coordinator also explains everything patients need to know to make an informed decision about whether or not to take part.



Kathryn Thomas, R.N., B.S.N., OCN, CCRP, Oncology Clinical Research Coordinator

For more information about clinical trials at the AtlantiCare Cancer Care Institute, call 609-677-7735.

NURSE NAVIGATOR'S CORNER

Ensuring a seamless care experience for patients and their families.

When you're fighting cancer, it's reassuring to have an advocate in your corner to help with appointment scheduling, specialist referrals, treatment side effects and other aspects of your care. At the AtlantiCare Cancer Care Institute, a Fox Chase Cancer Center Partner, patients are personally guided through the continuum of care by oncology nurse navigators such as Tracie Rodriguez, R.N., OCN.

Rodriguez is dedicated full time to the complex GI/lung/prostate cancer program at AtlantiCare. In this role, she is an integral member of the multidisciplinary patient care team for patients with prostate cancer, as well as those with colorectal cancer and other types of malignancies in the digestive system. Rodriguez works one on one with patients and their loved ones to coordinate all the necessary details before, during and after treatment.

"My passion for oncology nursing was inspired after my mother was diagnosed with breast cancer. That made it personal for me," Rodriguez says. "The role of oncology nurse navigator allows me to spend more time with patients and to direct them to the resources they need at the hospital or in the community."

In addition to providing individualized patient education, her specific responsibilities include enhancing access to services and helping patients overcome any barriers to care, such as transportation, insurance issues or language translation. Rodriguez is also there to promote the emotional and physical well-being of patients in addition to focusing on their medical needs.

"A lot of times," she adds, "people do not know where to turn or what to do when they first find out they have cancer. I am their go-to person to find them the answers they need. We have an amazing team of people, in addition to myself, here to support patients every step of the way. I am so fortunate to have the opportunity to make a difference in people's lives through this role."



"I have dedicated myself to providing individualized care to patients and their family members through the treatment, journey and beyond. I want those in my care to feel part of a family with me and with our team to help decrease their fear and heal with less worry during this stressful time."

Tracie Rodriguez joined AtlantiCare Regional Medical Center (ARMC) in 2002 and has provided patient care in various clinical areas, including the Oncology department at ARMC Mainland Division, the outpatient and inpatient operating rooms and recovery room at ARMC Surgery Center and the Radiation Oncology department of the AtlantiCare Cancer Care Institute. Most recently, she was the lead registered nurse working directly with James Wurzer, M.D., Ph.D., medical director of Radiation Oncology.

TAKING CARE AND GIVING BACK

In addition to specialized medical services for the diagnosis and treatment of cancer, community education and outreach are important elements in the service continuum at AtlantiCare Cancer Care Institute. AtlantiCare's community outreach in 2017 included support groups, cancer prevention and screening programs, and support of events and nonprofit organizations that benefit community members in the fight against cancer.

Community Education and Screening

- Health fair, workshops and educational lectures on various cancer-related topics
- Screening mammograms
- Skin cancer health assessments and prevention education events
- Low-dose CT lung cancer screenings
- "Survivors Are Our Superheroes" community event
- Somers Point Beach Concerts

Event Sponsorship and Participation

- American Cancer Society events
- American Heart Association
- Dean Randazzo Cancer Foundation, Paddle for a Cause
- Every Breath Counts, Lung Cancer Walk/Run
- Gilda's Club South Jersey events
- Ladies Invitational Blue Fish Tournament
- Ribbons of Hope
- Ruth Newman Shapiro Cancer and Heart Fund events
- Shirley Mae Run and Michael J. Walk
- Susan G. Komen events
- Tara Miller Melanoma Foundation Gala



ATLANTICARE CANCER COMMITTEE MEMBERS

The AtlantiCare Cancer Committee is composed of primary and specialty care physicians, as well as hospital staff and providers with a direct role in caring for our oncology patients. The multidisciplinary committee meets regularly to review and evaluate the quality and direction of the overall oncology program and makes recommendations for improvement.

Required Physician Members

Mitchell Brezel, M.D.

Diagnostic Radiologist

Anjeanette Brown, M.D., FACS

Surgeon

Neha Chawla, M.D.

Medical Oncologist

William Todd, M.D.

Pathologist

James Wurzer, M.D., Ph.D.

Medical Director, Oncology Program
Medical Director, Radiation Oncology
Cancer Committee Chairman
Cancer Liaison Physician

Required Non-Physician Members

Elizabeth Eble, D.N.P., A.P.N.

Palliative Care

Cheryl Eget, CTR

Cancer Registry Quality Coordinator
Supervisor, Oncology Data Services

Maria Hendricks, M.S.N., R.N., CCRP

Assistant Vice President,
Oncology Services
Regional Administrator, Central Market

Samantha Hill, M.S.W.

Psychosocial Services Coordinator
Social Worker

Nancy McGrath, RHIT, CTR

Cancer Conference Coordinator

Maria Victoria Roque, B.S.N., R.N., OCN

Quality Improvement Coordinator
Clinical Manager, Medical Oncology

Janine Sooy, R.N.

Quality Management Representative

DeAnnette Stanton-Cross, B.A., OPN-CG

Oncology Program Manager
Community Outreach Coordinator

Kathryn A. Thomas, R.N, B.S.N., OCN, CCRP

Oncology Clinical Research
Coordinator

Additional Members

Frank Carpenter

Corporate Director, Oncology
Operations

Carolyn Courtney, R.N.

Oncology Clinical Research Associate

Bruno Dantas, M.D.

Pathologist

Vicki DiStefano, R.N., OCN

Radiation Nurse

Kelly Filchner, M.S.N, R.N., OCN, CCRC

Fox Chase Cancer Center Liaison

Audrey Heist, M.P.H., RD

Director of Health Engagement

Juliann Henry, M.Div.

Pastoral Care Representative

Desiree Jangha, Ph.D, DABR

Director, Medical Physics,
Radiation Therapy Services

Taryn Jones, M.Ed.

American Cancer Society
Representative

Mary Law, M.S.N, R.N.

Assistant Vice President of
Quality/Accreditation

David Levi, M.D.

Diagnostic Radiologist

John Lorenzetti, M.D., FACS

Medical Director of Breast Program
Breast Surgeon

Alice Malfi, R.N., OCN

Radiation Oncology Nurse

Maria Marine

Oncology Data Services

Debra Meredith, R.N.

Hospice

Hien T. Nguyen, Pharm. D., BCPS

Pharmacist

Lacey Peterman

Director, Oncology Operations

Hannah Rizzo, RD

Registered Dietitian

Tracie Rodriguez, R.N., OCN

Nurse Navigator

Cheryl Rush, M.S.N., A.P.N.

Palliative Care

Cathy Sutman, M.S.W.

Psychosocial Services Coordinator
Social Worker

Vasthi Wilson, M.D., MSc

Radiation Oncologist



AtlantiCare Health Park
2500 English Creek Avenue, Building 400
Egg Harbor Township, NJ 08234



106 Court House South Dennis Road, Building 200
Cape May Court House, NJ 08210

1-888-569-1000
www.atlanticare.org/cancer

AtlantiCare
THE CANCER CARE INSTITUTE

A member of Geisinger

Fox Chase Cancer Center Partner



A QUALITY PROGRAM
of the AMERICAN COLLEGE
OF SURGEONS

